Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
10/2010
10/28/2010WO2010122171A1 5-heteroarylmethyl-i- (b-mercapto- [1,2, 4 -triazolylmethyl) -cyclopentanol as fungicides
10/28/2010WO2010122170A1 5-mercapto- [1,2,4] triazolylmethyl-cyclopentanol compounds and their agricultural and pharmaceuti al uses
10/28/2010WO2010122169A1 5-mercapto- [1,2, 4] triazole compounds and their agricultural and pharmaceutical uses
10/28/2010WO2010122167A1 5 -mercapto- [1, 2, 4] triazolylmethyl-cyclopentanol compounds and their agricultural and pharmaceutical uses
10/28/2010WO2010122162A1 Diaryl ethers
10/28/2010WO2010122151A1 3 -azabicyclo [4.1.0] heptanes used as orexin antagonists
10/28/2010WO2010122134A1 Nr2b-selective nmda-receptor antagonists
10/28/2010WO2010122109A1 Method for the treatment of acute myeloid leukemia
10/28/2010WO2010122091A1 Thia-triaza-as-indacenes as pi3-kinases inhibitors for the treatment of cancer
10/28/2010WO2010122089A1 N-pyrazolyl carboxamides as crac channel inhibitors
10/28/2010WO2010122088A1 Pyrazole and triazole carboxamides as crac channel inhibitors
10/28/2010WO2010122087A1 Methods for improving pharmacokinetics
10/28/2010WO2010122082A1 Heterocyclic antiviral compounds
10/28/2010WO2010122071A1 Thia-triaza-cyclopentazulenes as pi3-kinases inhibitors for the treatment of cancer
10/28/2010WO2010122069A1 5-alkynyl-pyridines
10/28/2010WO2010122064A1 Substituted naphthyridine derivatives and their medical use
10/28/2010WO2010122038A1 Inhibitors of bruton's tyrosine kinase
10/28/2010WO2010122012A1 Thioxanthene derivatives for the treatment of infectious diseases
10/28/2010WO2010121995A1 3,3'-spiroindolinone derivatives and their use for cancer
10/28/2010WO2010121980A1 Use of nifuratel to treat infections caused by atopobium species
10/28/2010WO2010121973A1 Blockers of nmda receptor for the treatment of sickle cell anemia
10/28/2010WO2010121969A1 Method of treating or preventing a convulsive disorder in a patient in need thereof
10/28/2010WO2010121963A1 Resorcinol derivatives as hsp90 inhibitors
10/28/2010WO2010121877A2 Process for the preparation of olopatadine
10/28/2010WO2010121834A2 Irak kinase family as novel target and biomarker for alzheimer
10/28/2010WO2010121762A1 Paracetamol for parenteral administration
10/28/2010WO2010121700A1 Compositions containing hyaluronic acid, sulphated hyaluronic acid, calcium and vitamin d3 for the treatment of osteoarticular and musculoskeletal disorders
10/28/2010WO2010121646A1 Heterocyclic compounds as mek inhibitors
10/28/2010WO2010121621A1 Liquid formulations of salts of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine
10/28/2010WO2010121619A1 Chewing gum and particulate material for controlled release of active ingredients
10/28/2010WO2010121575A1 Oxalato complexes of platinum
10/28/2010WO2010121570A1 Methyl cantharimide compounds, treatment method using them and their preparation method
10/28/2010WO2010121503A1 Tacrolimus injection preparation
10/28/2010WO2010121487A1 Preparation and use of novel antibiotic, anticancer compounds and derivatives thereof
10/28/2010WO2010121486A1 Prodrugs based on gemcitabine structure as well as synthetic method and application thereof
10/28/2010WO2010121391A1 Solid food comprising dietary fiber and/or foodstuff rich in dietary fiber, preparation and use thereof
10/28/2010WO2010121379A1 Treatment of ovarian cancer using an anticancer agent conjugated to an angiopep-2 analog
10/28/2010WO2010121352A1 Use of (hexenoyl trans-3)hgrf(l-44)nh2 and simvastatin in combination therapy
10/28/2010WO2010121351A1 Use of (hexenoyl trans-3)hgrf(1-44)nh2 and ritonavir in combination therapy
10/28/2010WO2010121334A1 Active substances-carrying pharmaceutical composition
10/28/2010WO2010121328A1 A novel formulation of indomethacin
10/28/2010WO2010121327A1 A novel formulation of diclofenac
10/28/2010WO2010121326A1 A novel formulation of naproxen
10/28/2010WO2010121325A1 A novel formulation of meloxicam
10/28/2010WO2010121324A1 A novel formulation of metaxalone
10/28/2010WO2010121323A1 Method for the production of commercial nanoparticle and microparticle powders
10/28/2010WO2010121321A1 Method for improving the dissolution profile of a biologically active material
10/28/2010WO2010110646A8 Aurones as selective pde inhibitors and their use in neurological conditions and disorders
10/28/2010WO2010096264A9 Methods for enhancing hematopoietic stem/progenitor cell engraftment
10/28/2010WO2010093889A3 Solid forms of 2-(2, 4-difluorophenyl)-6-(1-(2,6-difluorophenyl)ureido)nicotinamide
10/28/2010WO2010093849A3 Phenylalanine amide derivatives useful for treating insulin-related diseases and conditions
10/28/2010WO2010091981A3 Products comprising n-phenylpropenoyl amino acid amides and uses thereof
10/28/2010WO2010083307A3 Synergistic fungicidal compositions including hydrazone derivatives and copper
10/28/2010WO2010082214A3 Fenofibrate formulation with enhanced oral bioavailability
10/28/2010WO2010081070A3 Novel forms of eperisone
10/28/2010WO2010080977A3 Oral sustained release antidepressant formulation
10/28/2010WO2010080577A3 Oxepine modulators of h1 receptors and/or inhibitors of mast cell degranulation
10/28/2010WO2010078285A3 Pharmaceutical compositions and methods of treating neurological insults
10/28/2010WO2010077976A3 Prokineticin receptor antagonists and uses thereof
10/28/2010WO2010077882A3 Antagonists of lysophosphatidic acid receptors
10/28/2010WO2010077317A3 Protease inhibitors
10/28/2010WO2010075287A3 Compounds and methods for the treatment of pain and other diseases
10/28/2010WO2010074480A3 Novel pyrazolodiazepine compounds as a transglutaminase inhibitor, the preparation method thereof and a composition containing the same
10/28/2010WO2010070665A3 A process for nanoemulsification of curcumin and derivatives of curcumin
10/28/2010WO2010068815A3 Compositions and methods for treating cellular proliferative disorders
10/28/2010WO2010068750A3 Compositons and method for treatment of mood and cognitive impairments
10/28/2010WO2010068708A3 3'-azido purine nucleotide prodrugs for treatment of viral infections
10/28/2010WO2010060967A3 Compositions and methods for treating retrovirus infections
10/28/2010WO2010058426A3 Inhibition of vegf-a secretion, angiogenesis and/or neoangiogenesis by sina mediated knockdown of vegf-c and rhoa
10/28/2010WO2010053974A3 Stable organic peroxide compositons
10/28/2010WO2010042755A3 Chimeric therapeutics, compositions, and methods for using same
10/28/2010WO2009150530A3 Pharmaceutical composition suitable for use as foam comprising 5'-aminosalicylic acid and silicone oil
10/28/2010WO2009143175A3 Sensory-specific local anesthesia and prolonged duration local anesthesia
10/28/2010WO2009142732A3 Substituted pyridazinone derivatives as histamine-3 (h3) receptor ligands
10/28/2010WO2009141321A3 Tablettable chewing gums comprising nicotine and a buffering agent
10/28/2010WO2009141090A8 {f-19} -labeled l-glutamic acid and l-glutamine derivative (iii), use thereof and method for obtaining them
10/28/2010WO2009140089A8 Sulfone compounds which modulate the cb2 receptor
10/28/2010WO2009135951A3 Process for preparing a tablet comprising metformin
10/28/2010WO2009133352A3 Lipid composition
10/28/2010WO2009127338A8 Oxo-heterocyclic substituted carboxylic acid derivates and the use thereof
10/28/2010WO2009121946A3 Process for the preparation of optically enriched clopidogrel
10/28/2010WO2009120789A8 Bicyclic nitroimidazoles covalently linked to substituted phenyl oxazolidinones
10/28/2010WO2009117515A8 Novel compounds advantageous in the treatment of central nervous system diseases and disorders
10/28/2010WO2009114814A3 Therapeutic substances that modulate genome methylation
10/28/2010WO2009114325A4 Methotrexate adjuvants to reduce toxicity and methods for using the same
10/28/2010WO2009106997A9 Amorphous arformoterol l-(+)-tartrate
10/28/2010WO2009076553A8 Composition of aqueous buffer solution for the treatment of cellular environment and ion channels and methods for using same
10/28/2010WO2007028030A3 Oncogenic regulatory rnas for diagnostics and therapeutics
10/28/2010US20100274215 Flushing solution
10/28/2010US20100274051 Inflammatory cytokine release inhibitor
10/28/2010US20100274026 Virus therapeutic drug
10/28/2010US20100274025 Methods and compounds for producing dipeptidyl peptidase iv inhibitors and intermediates thereof
10/28/2010US20100273895 Formulations of cannabidiol and prodrugs of cannabidiol and methods of using the same
10/28/2010US20100273894 Treatment of leber's hereditary optic neuropathy and dominant optic atrophy with tocotrienol quinones
10/28/2010US20100273893 Protective effect of thymoquinone in spesis
10/28/2010US20100273892 Formulations of tocotrienol quinones for the treatment of ophthalmic diseases
10/28/2010US20100273891 Isoflavone metabolites
10/28/2010US20100273890 Identification of bacterial autoinducer and use in treating bacterial pathogenicity
10/28/2010US20100273889 Use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas
10/28/2010US20100273887 Mixtures comprising pellitorin and uses thereof
1 ... 2028 2029 2030 2031 2032 2033 2034 2035 2036 2037 2038 2039 2040 2041 2042 2043 2044 2045 2046 2047 2048 ... 7860